More than two million illnesses and 23,000 deaths are attributed to infections with antimicrobial-resistant organisms in the United States each year, which translates to approximately 260,000 illnesses and nearly 3,000 deaths among Californians. Infections with resistant organisms are more difficult to treat and are associated with prolonged hospital stays and greater disability and death compared with infections caused by susceptible organisms. There are currently few antibiotics left in the treatment arsenal against resistant infections and even fewer new drugs in the development pipeline. To address this serious national public health problem, in September 2014, President Obama issued an Executive Order "Combating Antibiotic-Resistant Bacteria", creating a multi-agency Task Force to detect and prevent illness and death related to antibiotic-resistant infections by implementing measures to reduce the emergence and spread of resistant bacteria and to help ensure continued availability of effective therapeutics for treatment. Please click on the links below to learn about the CDPH HAI Program's work to address this in California.
In the Center for Disease Control and Prevention (CDC)'s Antibiotic Resistance Threats in the United States, 2013 Report, two healthcare-associated pathogens, Clostridium difficile (C. difficile) and carbapenem-resistant Enterobacteriaceae (CRE), are highlighted as requiring Urgent attention. These organisms are considered high-consequence threats because of multiple factors, including minimal progress in past efforts to decrease C. difficile infections and the lack of available treatment options for many CRE infections.
Information on CDI:
Information on CRE:
CDC's Threat Report classifies MRSA as a Serious threat. Staph bacteria, including methicillin-resistant stapylococcus aureus (MRSA), are one of the most common causes of healthcare-associated infections. Although still common and severe threat to patients, invasive MRSA infections in healthcare settings appear to be declining. This success began by the focused prevention of central-line associated bloodstream infections, many of which were due to MRSA.
Information on MRSA:
Core actions to prevent resistance include improving antimicrobial prescribing through stewardship, reducing infections, and preventing transmission of resistant bacteria.
Information on Antimicrobial Stewardship:
Information on Infection Prevention Resources:
Information on Antimicrobial Resistance Laboratory Resources:
| Conditions of Use